In December 2018, the National Institute of Standards and Technologies (NIST) (a part of the Department of Commerce) published a draft Green Paper, titled “Return on Investment Initiative for Unleashing American Innovation” (NIST Special Publication 1234). A copy of the draft Green Paper is available here: https://doi.org/10.6028/NIST.SP.1234 The draft Green Paper was published after the launch of an April 2018 initiative, “Unleashing American Innovation Symposium” and followed four public hearings and a request for comments noticed on May 1, 2018 (83 FR 19052). The initial comment period closed July 30, 2018. UACT drafted a letter to raise the alarm in members of Congress that anRead More →

On Wednesday December 5, 2018, UACT, along with KEI, Social Security Works, Health GAP, Public Citizen, Dr. Ophira Ginsburg, and James Love, submitted joint comments in response to a proposed exclusive license for patents on CAR T technology for the treatment of cancers. The Federal Register notice (83 FR 58262) “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like Tyrosine Kinase 3 (FLT3) Expressing Cancers,” outlined the National Institutes of Health’s intent to grant an exclusive license on these technologies to ElevateBio, a company whose leadership includes the investors behind recent budget-breaking treatments,Read More →